Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussion around the FLOW trial is enthusiastic and highly engaged, focusing on the demonstrated reductions in major kidney events, cardiovascular deaths, and slower kidney decline among patients with type 2 diabetes and CKD. The tone is celebratory and informational, with frequent citations to NEJM results and conference discussions, and some critical notes about study design, sources, or cost. Examples include mentions of HR 0.76 for primary kidney outcomes, 24% lower risk, and references to NEJM and ERA discussions, showing how word choice (reductions, risk, benefits), tone (celebratory, cautious), and context (publications, conferences) shape a view of substantial clinical impact.
Most posts express overall agreement with FLOW trial findings, praising benefits for CKD and cardiovascular outcomes, with a few cautious notes about sources or cost.
High interest across the board, with numerous posts highlighting key results, NEJM publication, and implications for practice.
High engagement: many posts reference data points (HRs, percentages), discuss ERA/NEJM presentations, and share links and discussions, indicating active dialogue.
Moderate to high perceived impact: conversations emphasize potential clinical benefits and policy/public health implications, though some skeptical or contextual cautions about commercial influences and generalizability.
Effects of Once-Weekly
Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPte Editorial: Diabetic Kidney Disease — Semaglutide Flows into the Mainstream https://t.co/64g6RdUWfj #Nephrology https://t.co/SaikYSqjEe
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease https://t.co/c7AuTCM7He https://t.co/kRPGFfbq3E
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZCTiLFA5
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZCTiLFA5
Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (https://t.co/m7Mo9hEruE), kidney disease (https://t.co/acauBtOjVt), osteoarthritis (https://t.co/8GcpZybcHh), heart failure (https://t.co/oulxMcXNco), and
Explores weight loss from semaglutide in obesity over 68 weeks and how most of the gains fade during a 1-year withdrawal, with diminishing cardiometabolic benefits. Highlights the need for ongoing care to sustain health…
Examines how semaglutide reduces major kidney events in type 2 diabetes with CKD, showing lower risk and slower decline in kidney health. Highlights potential cardiovascular mortality reduction and clinical implications…
Recent results from the FLOW study investigate the renal effects of semaglutide in patients with type 2 diabetes and chronic kidney disease. The study observed a 24% reduction in major kidney events and improved kidney…
This video explores the effects of GLP1 agonists like Ozempic and Mounjaro, originally designed for diabetes management, on weight loss and overall health. It highlights recent research showing semaglutide's ability to…
Overview of semaglutide's kidney-protective effects in type 2 diabetes with CKD, based on the FLOW trial results and NEJM publication, and its potential role alongside other therapies in preserving renal health.
In a special webinar in cooperation between MARKUS HOMe and Nephrology Dialysis and Transplantation, experts discuss landmark studies from the ERA 2024 convention in Stockholm. The focus includes the promising results…
Prof Johannes Mann presents the FLOW study results demonstrating the nephroprotective effects of Semaglutide in 3533 chronic kidney disease patients, emphasizing recent advances in managing blood pressure in CKD.
This podcast covers vulnerable plaque, industry payments to trainees, and the trial design of tirzepatide versus dulaglutide. Insights on major adverse cardiovascular events in type 2 diabetes patients are discussed…
The study FLOW investigates the renal effects of semaglutide in patients with type 2 diabetes and chronic kidney disease, showing a 24% reduction in major kidney events and improved kidney and cardiovascular health.
This video delves into the core concepts of quantum mechanics, focusing on fundamental principles that govern the behavior of matter and energy at microscopic scales. Viewers will gain insights into wave-particle…
Semaglutide reduces risks of kidney failure, cardiovascular problems, and death in patients with type 2 diabetes and chronic kidney disease, showing significant improvements in kidney health and slowing disease…
@ChaseResults1 https://t.co/Z3sCW00gAz
Primary Evidence: Pratley RE, Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024; 391:109-121. PMID: 38785209. Follow @straightfromdox for daily EBM.
3,533 people with type 2 diabetes and kidney disease were given semaglutide or a placebo. Over 3.4 years, kidney failure, a large drop in kidney function, or death from kidney or heart causes were 24% less likely on the drug. https://t.co/4CW2RZbmEG https://t.co/kzVV9tld88
FLOW deserves more attention. Over a median 3.4 years in adults with type 2 diabetes and kidney disease, semaglutide lowered the combined risk of major kidney events or cardiovascular death vs placebo. Serious adverse events were less frequent. https://t.co/5AU7QTtLdU https://t.co/CACJPWBNRS
Aquí te dejo los links: Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. https://t.co/FFML8Z3PaX Wong CK, Drucker DJ. Antiinflammatory actions
Class meta-analysis: https://t.co/iutd65eCaa FLOW primary: https://t.co/07OMM27AEf FLOW SGLT2 analysis https://t.co/pOFKsfQZQ1
Sources: SELECT cardiovascular outcomes: https://t.co/7QefVDbZBQ FLOW kidney outcomes: https://t.co/QFsH5N2hnJ Rotator cuff repair cohort: https://t.co/K7kQQPs15d
https://t.co/14MVVqosn7
Perlas en enfermedad renal crónica !!! GLP-1 RA en ERC: el beneficio renal persiste incluso en ERC avanzada Los análisis más recientes del estudio FLOW muestran que semaglutida reduce eventos renales mayores y mortalidad por cualquier causa de forma consistente a través de
? References & Further Reading The thread above is a thought experiment about the potential public-health implications of broadly accessible GLP-1 therapies. The underlying evidence comes from a rapidly expanding body of clinical research: • Wilding JPH et al. (2021).
The FLOW Trial: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/1CytOTf7ON
pubmed.ncbi.nlm.nih.gov/38785209/ for the DKD trial - this is just the first of a few more on the way Also reduces mortality (~ 20%) in these patients Apart from effects on the heart, knee pain, sleep apnea (all RCT data)
https://t.co/mqqLXEeay6
https://t.co/ESlTEDIvHJ
https://t.co/EMKsaFrLG8
@cwhogg @maxmarchione Here’s a couple just off the list I keep for clients: - Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. - Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. -Perkovic V, et al. (2024).
Revolución en Cardiorrenal (Evidencia del Ensayo FLOW) ? Cambio de paradigma en ERC y Diabetes Tipo 2. Los resultados del ensayo FLOW confirman que la semaglutida (GLP-1 RA) reduce significativamente el riesgo de eventos renales mayores y mortalidad cardiovascular. Ya no es
Reduced Risk of Major Adverse Cardiovascular Events (MACE) Heart disease is the number 1 cause of death in the US. Patients with diabetes are at a much higher risk of cardiovascular disease than the general population. Therapies that can reduce the risk of cardiovascular disease https://t.co/2zSAN9NYIP
Nope! Article links to a few places but the first screenshot seems to be one of the studies. The next three are excerpts from the NatGeo human trials.
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
RT @edgarvlermamd: Effects of Once-Weekly
Effects of Once-Weekly
Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal #NephSky
Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal #NephSky ? pubmed.ncbi.nlm.nih.gov/38785209/ ? pubmed.ncbi.nlm.nih.gov/27633186/ ? pubmed.ncbi.nlm.nih.gov/39081763/ Nice write up here by @kidneyboy.bsky.social ? www.docwirenews.com/post/peeking...
Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal #VisualAbstract by @AnjanaGopal9 @kidney_boy @brian_rifkin FLOW
RT @5_utr: The FLOW trial. Nephrologists don’t mess around with their trial acronyms do they @ChristosArgyrop at least it’s not the Kidney…
The FLOW trial. Nephrologists don’t mess around with their trial acronyms do they @ChristosArgyrop at least it’s not the Kidney disease Advancement Limiting Experiment (KALE) trial https://t.co/UN6EViq9QY
@DrTurdFerguson_ If by "cook" you mean "improve the health of, then yes. "The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group" https://t.co/oCSTscRqQI
@ClickingSeason Except in the studies, even when you didn’t control for diet, the people were healthier. The fat and excess is the main problem, more so than the diet https://t.co/3MOOcmN0rP
@IterIntellectus Actually in the studies people who took ozempic were healthier irregardless of what they ate https://t.co/3MOOcmNyhn It’s the fat
DOI: 10.1056/NEJMoa2403347
3/
RT @mvaduganathan:
RT @EricTopol: How to reduce deaths and kidney disease in patients with Type 2 diabetes? Report of a new GLP-1 randomized trial @NEJM https…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
https://t.co/2PTlGmKgZe
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease https://t.co/c7AuTCM7He https://t.co/kRPGFfbq3E
RT @FarmaMadridAP: (JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 t…
RT @FarmaMadridAP: (JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 t…
RT @FarmaMadridAP: (JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 t…
RT @FarmaMadridAP: (JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 t…
RT @FarmaMadridAP: (JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 t…
RT @FarmaMadridAP: (JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 t…
RT @FarmaMadridAP: (JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 t…
(JAMA) La FDA aprueba semaglutida para reducir el riesgo de progresión de la enfermedad renal, https://t.co/tCm26QQvS6 tras los resultados del EC https://t.co/Ky8ct5u2bC
RT @gabi_puchepalao:
RT @NefroClassMx: Semaglutida ↓ eventos renales mayores en DM2+ERC (↓ ≥50% eGFR, ERT, eGFR <15, o muerte renal/cardiovascular.) (HR 0.76; I…
RT @NefroClassMx: Semaglutida ↓ eventos renales mayores en DM2+ERC (↓ ≥50% eGFR, ERT, eGFR <15, o muerte renal/cardiovascular.) (HR 0.76; I…
RT @NefroClassMx: Semaglutida ↓ eventos renales mayores en DM2+ERC (↓ ≥50% eGFR, ERT, eGFR <15, o muerte renal/cardiovascular.) (HR 0.76; I…
RT @NefroClassMx: Semaglutida ↓ eventos renales mayores en DM2+ERC (↓ ≥50% eGFR, ERT, eGFR <15, o muerte renal/cardiovascular.) (HR 0.76; I…
Semaglutida ↓ eventos renales mayores en DM2+ERC (↓ ≥50% eGFR, ERT, eGFR <15, o muerte renal/cardiovascular.) (HR 0.76; IC95% 0.66–0.88; p=0.0003). También ↓ MACE (HR 0.82) y mortalidad total (HR 0.80). Menos EA graves (49.6% vs 53.8%). NEJM 2024. DOI: 10.1056/NEJMoa2403347 https://t.co/qabmHKswJo
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @gabi_puchepalao:
RT @mvaduganathan:
@tracewoodgrains We just need to get these mother fuckers on ozempic and later maybe retatrutide. https://t.co/rWpOk9Wbls
セマグルチド、CKD+2型糖尿病に有効 https://t.co/Z5E19hAUR0 FLOW試験 主要腎イベント↓24%（HR 0.76, 95%CI 0.66-0.88） 心血管死↓29%（HR 0.71, 95%CI 0.56-0.89） 腎機能低下抑制＆死亡率改善。 GLP-1RAはCKDの新たな治療選択肢に https://t.co/VWJpxPdckY
Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. https://t.co/R0oEq1DX7V https://t.co/zr4PkCbLef
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @drbennisahmed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clini…
RT @JamiePollo56820: @MichaelAlbertMD The FLOW trial, which investigated the effects of semaglutide on chronic kidney disease in patients w…
@MichaelAlbertMD The FLOW trial, which investigated the effects of semaglutide on chronic kidney disease in patients with type 2 diabetes, was funded by Novo Nordisk, the manufacturer of semaglutide. The company managed trial operations and conducted the analyses, which were independently
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease https://t.co/c7AuTCM7He https://t.co/GjY9QeHjDd
Thank you @KatherineTuttl8 for presenting #FLOW at HOMe back in May! https://t.co/8jt8HedA0A https://t.co/j2IpiFH24Y
TOP 1: FLOW by Drs. @VladoPerkovic, @RpratleyMD et al. https://t.co/ULuWhRzsBA In patients with type 2 diabetes and chronic kidney disease, semaglutide reduced CKD progression and cardiovascular death. https://t.co/VsE2mQV4u6
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/Dj9dXBWeEf
RT @NEJM: Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significant…
RT @NEJM: Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significant…
RT @NEJM: Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significant…
RT @NEJM: Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significant…
Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. https://t.co/Q9DAA6mPte https://t.co/eH0XIgTnmO
@totalimmunity @BEisenhart You have a conspiracy between the NEJM and the Economist, and I can easily find others. That's crazy. https://t.co/pBPOR4VCLe
@thejeebuzcrust @SideGravy @DavidLund6 @BEisenhart That is not a source. One of my sources is NEJM, which is independent. There is no way that conspiracy mongers will trust science, but for others. https://t.co/pBPOR4VCLe
RT @Inaaqc_bo: ATEROMA (ASOBAT)|
RT @Obesidades_mx: @ConscienHealth -Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N…
@ConscienHealth -Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. -Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2024.
ATEROMA (ASOBAT)|
@bulkbiker @DrEenfeldt You simply are unaware of the evidence. There are two 4-year trials showing it's beneficial for staying alive and healthy. Yes, there are adverse effects, but IMO they aren't even close to outweighing the benefits. https://t.co/g01mND2nzh https://t.co/m4HlNPuhj8
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
3/14 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes... https://t.co/ilO4yYmp4E
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
RT @DrAkhilX: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZC…
RT @DrAkhilX: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZC…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes 2 https://t.co/7t3A1twi9h
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
RT @DrAkhilX: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZC…
RT @DrAkhilX: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZC…
RT @SamuelBHume: Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (ht…
Thank you for reading! Sources as follows: 1. GLP1R agonists for diabetes (https://t.co/l9DEd33w5Z), liver fibrosis (https://t.co/m7Mo9hEruE), kidney disease (https://t.co/acauBtOjVt), osteoarthritis (https://t.co/8GcpZybcHh), heart failure (https://t.co/oulxMcXNco), and
RT @DrAkhilX: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZC…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZCTiLFA5
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/3NiRyNwBuU https://t.co/zhZCTiLFA5
RT @CristobMorales: https://t.co/8KCpwiOS77 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Directamente…
RT @CristobMorales: https://t.co/8KCpwiOS77 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Directamente…
RT @jorgericof: Carta al editor . Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Tomas Rodríguez-Yánez, María J. Soler, published the paper: Eff…
RT @jorgericof: Carta al editor . Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Tomas Rodríguez-Yánez, María J. Soler, published the paper: Eff…
RT @jorgericof: Carta al editor . Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Tomas Rodríguez-Yánez, María J. Soler, published the paper: Eff…
RT @jorgericof: Carta al editor . Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Tomas Rodríguez-Yánez, María J. Soler, published the paper: Eff…
RT @jorgericof: Carta al editor . Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Tomas Rodríguez-Yánez, María J. Soler, published the paper: Eff…
Carta al editor . Jorge Rico-Fontalvo, Rodrigo Daza-Arnedo, Tomas Rodríguez-Yánez, María J. Soler, published the paper: Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. Nefrología Latinoamericana @PepaSolerR https://t.co/0MgR3DuAxT https://t.co/7nssxCnsmG
https://t.co/8KCpwiOS77 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Directamente del @NEJM a la Ficha técnica… cuando la ciencia acerca la innovación a los pacientes #FLOWtrial @NovoNordiskES https://t.co/pDxekt9CII https://t.co/MmZQ24J5yz
6. If by benefits of the drug you mean weight, glycemic, cardiac, renal, vascular, and OA (among other forthcoming indications), the impacts are persistent: https://t.co/mPQur3Hjzy https://t.co/p4k8UTTuMQ https://t.co/XNvGAzKWur https://t.co/dvV9IH2EHE https://t.co/BHSslgz3Xr
RT @Vasuragh: We participated in a FLOW Study on effects of Semaglutiden on CKD. It was an amazing experience working and contributing. h…
#3 with @altmetric score of 2826 and 110 citations, semaglutide makes another appearance! Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. Another game changer. Patients with type 2 diabetes and CKD randomized to semaglutide had a 4% absolute
RT @Vasuragh: We participated in a FLOW Study on effects of Semaglutiden on CKD. It was an amazing experience working and contributing. h…
RT @Vasuragh: We participated in a FLOW Study on effects of Semaglutiden on CKD. It was an amazing experience working and contributing. h…
We participated in a FLOW Study on effects of Semaglutiden on CKD. It was an amazing experience working and contributing. https://t.co/IeipPcitEu https://t.co/cdckobnY69
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. - Kidney International Reports https://t.co/IKOqCWHvHA
@feafij @Rohanburdened @est_magnetique @clairlemon “Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.” Funded by Novo Norodisk, but this study shows semaglutide reducing kidney issues. https://t.co/t9q1xeDMmn
The 3rd surprising benefit of GLP1s--they can improve kidney function! https://t.co/stj8HbNVwU #GLP1 #tirzepatide #semaglutide Stay tuned for 7 more benefits! From Hormonal Well-Being 713-714-7523 https://t.co/fsHSEdYsVm
@daley63965 @Nallysmom @DrSyedHaider @naomirwolf https://t.co/BL1GtBQMwJ Conclusions: Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease
Don’t forget DKD! www.nejm.org/doi/full/10....
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
@otis_reid The kidney disease savings could big, but of course the drugs cost a lot too https://t.co/jrxNAq5ZR9
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/jrTkHVbeqh
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
GLP-1受容体作動薬のセマグルチドの腎保護作用が報告されました。2型糖尿病の慢性腎臓病患者さんの治療薬がまた１つ増えましたね。RAS阻害薬しかなかった時代からこの10年で大きく変わりました。 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
RT @com_SFNDT:
Life extending therapy for Chronic #Kidney disease for people with #type2diabetes‼️ Check out our #YouTube review of the pivotal FLOW trial #semagultide Should we all go with the FLOW❓ ? youtu.be/QZssLxRKAQE
Life extending therapy for Chronic #Kidney disease for people with #type2diabetes‼️ Check out our #YouTube review of the pivotal FLOW trial #semagultide Should we all go with the FLOW❓ ? https://t.co/4rhM3pfoO9 @kamleshkhunti @AliceYYCheng @DSNforumUK https://t.co/c0Tr2PeYuM
RT @ValleAlfonso:
@dgfn_ev @MenkeWeinmann https://t.co/fJajbvZgkm
Full text links Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Authors: Vlado Perkovic, M.B. et al https://t.co/57Xs3ldD6q Resumen disponible en formato pdf
Acceso a bibliografia comentada en @PubMedOnline https://t.co/40RYnRHgTW
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/FIeohLrexf
RT @ASPNeph: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/A36c3DA8Au #CKD @NEJM
RT @dr_ukio: ★FLOW試験の結果がERA /NEJMで同時発表されました！ 2型DM+CKD (eGFR 25-75 / UACR 100-5000) 3533人(66歳、アジア24%) セマグルチド注射1.0mg vs プラセボ 3.4年 主要複合イベント(…
RT @ASPNeph: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/A36c3DA8Au #CKD @NEJM
RT @ASPNeph: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/A36c3DA8Au #CKD @NEJM
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/A36c3DA8Au #CKD @NEJM
It is noted that discontinuation of #Semaglutide or placebo in the #FLOW trial occurred in 26% of the patients, while adherence rate was 89% @BSHeartFailure @Ahmed742Iqbal @NEJM @SheffieldHosp @RCPEdin #CardioTwitter https://t.co/TeQA3FamsO
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/FIeohLrexf
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/g6yWh82iP3
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/aZta87C9il
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/fNilmF6gvh
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/KPL6mbrDYi
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/iBt7FOgQpn
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/OzmtjBZOYJ
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/4TUeODwKJz
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @ISRNM_Social: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/8rePKsiVhN
なんとGLP1には腎保護効果もあるらしい。 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/dMkZD9We7l
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
RT @NEJM: Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPt…
Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPte Editorial: Diabetic Kidney Disease — Semaglutide Flows into the Mainstream https://t.co/64g6RdUWfj #Nephrology https://t.co/SaikYSqjEe
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/8rePKsiVhN
https://t.co/4OShH6gENg
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/QpnOh385Kb
3) This program focuses on the #FLOW trial recently published in the @NEJM by @VladovPerkovic: Effects of #Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes, at https://t.co/sKuZ162ATj.
Have you read the new FLOW trial on the effects of semaglutide on chronic kidney disease in patients with type 2 diabetes? Check out some of the highlights here! #pharmacy #diabetes #chronickidneydisease #ambulatorycare https://t.co/oX0L1OOSAK
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/ppjnjS1RLj
RT @schumacherbj: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/CURAQY1icw
RT @P_Rossing: Presentation of FLOW today @ADA in Orlando with New data so stay tuned! Effects of Semaglutide on Chronic Kidney Disease in…
RT @P_Rossing: Presentation of FLOW today @ADA in Orlando with New data so stay tuned! Effects of Semaglutide on Chronic Kidney Disease in…
Presentation of FLOW today @ADA in Orlando with New data so stay tuned! Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/gCN7bwbOhO
Huge privilege to engage in thus conversation! @ERAkidney @KatherineTuttl8 @AKronbichler @gunnar_heine @Tobias_B_Huber @ISNkidneycare 61th European Renal Association (ERA) Congress - Prof. K. R. Tuttle, Dr.... https://t.co/UA8QL0OMsP via @YouTube
腎臓にもよい。今までは心血管イベントが主要アウトカムのRCTしか結果がなかったのかな？ T2DMのある患者のCKDに対するセマグルチドの効果 https://t.co/TJuNz5qivO
RT @ValleAlfonso: ? Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes @NEJM ‼️ ?3533 ↘️24% lower in the se…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease https://t.co/c7AuTCM7He
FLOW study https://t.co/RNV8FbNCCX
Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes | comment: Peter Lin MD, CCFP https://t.co/yLqDOjXpd8 vía @practiceupdate
Link zur Publikation: https://t.co/LgXbUzokYJ
@NEJM FLOW trial Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes DMありCKDに対するSemaglutideの腎保護効果 @NEJM (2024) https://t.co/q9hQ9OWgWe
2/10 What did I miss? In trials of CV outcomes, GLP-1 agonists have shown promise in reducing proteinuria. The FLOW trial evaluated the use of semaglutide in reducing major adverse kidney outcomes (MAKE) in patients with CKD and DM2. https://t.co/464escIi4g
FLOW is the first primary kidney outcome trial of a GLP1-RA. Semaglutide demonstrated a lower risk of kidney events, cardiovascular events, and all-cause mortality compared to placebo. https://t.co/QcMB5JwoKw
RT @NephJC: Do not forget to look at the @NEJM article before we start. Click the
Do not forget to look at the @NEJM article before we start. Click the
Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. https://t.co/6NA5YBNLz4 #ckd #diabetes #health #medicine
Do not forget to look at the @NEJM article before we start. Click the
RT @dra_miliflores: Ready for #NephJC discussion✅
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/vtoSgC67XW
RT @dra_miliflores: Ready for #NephJC discussion✅
RT @dra_miliflores: Ready for #NephJC discussion✅
RT @dra_miliflores: Ready for #NephJC discussion✅
RT @dra_miliflores: Ready for #NephJC discussion✅
RT @dra_miliflores: Ready for #NephJC discussion✅
RT @dra_miliflores: Ready for #NephJC discussion✅
RT @dra_miliflores: Ready for #NephJC discussion✅
Ready for #NephJC discussion✅
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/be7kGTn7NI
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/BNaCFJFlOG
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/KGscMidYGR
If you missed or felt overwhelmed by the best clinical trial sessions at #ERA24, make sure to watch this excellent MARKUS at HOMe discussion! Kudos to @Tobias_B_Huber and @KatherineTuttl8 ? https://t.co/NdsadjCep7
In this special webinar in cooperation between MARKUS @ HOMe and @NDTsocial , @KatherineTuttl8 , @valerie_luyckx and @Tobias_B_Huber discuss landmark studies presented at #ERA24. great conversation! https://t.co/vr0kVhmSSu
糖尿病および慢性腎症患者に対するGLP-1作動薬（セマグルチド）の腎不全、心血管イベント、死亡リスクの低減効果（New Engl J Med） ☑︎ セマグルチド1700人、プラセボ1700人の大規模RCTで追跡期間の中央値は3.4年 ☑︎ 各アウトカムのリスクは軒並み約20％低減した https://t.co/7ZeTK6JbwT
2型糖尿病のCKDに対するセマグルチド https://t.co/RNV8FbNCCX
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/sPDXkohNLF
Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes | comment: Peter Lin MD, CCFP https://t.co/D1UV5ALFCh vía @practiceupdate
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/goRk5PAqF6 #glp1 #endocrinology #diabetes #nephrology #endotwitter #medtwitter
【RCT】eGFR50-75mL/min/1.73m^2かつ300<UACR<5000mg/gまたは25≤eGFR<50かつ100<UACR<5000のCKDを伴う2型糖尿病患者へのセマグルチド皮下注投与は、プラセボの投与と比較して、主要腎臓イベントリスクを減少させた。 #ペ読 https://t.co/zDeSkchXmn
https://t.co/CuiG3yT51d
Thanks also to all their co-authors - comprising (but not limited to) @hengel_f @NicolaMTomas @moritz_lasse @mrins01 @LoretoGesualdo @pi_ronco @VladoPerkovic @RpratleyMD and surely Johannes Mann (with whom we recorded a ???????? discussion on FLOW https://t.co/zVUaQNBZrF ).
"Victory belongs to the most tenacious" Thank for the great summary on the "Best Convention Ever" (Danilo Fliser) by @KatherineTuttl8 @valerie_luyckx @Tobias_B_Huber! https://t.co/ExM983JjaS https://t.co/MturcwhKHz
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/YlGuyAsixF
Don't stop the FLOW after #ERA24! A Markus@Home with Profs @KatherineTuttl8 @valerie_luyckx and @Tobias_B_Huber on key studies presented during the past meeting in Stockholm! For those who missed the FLOW trial presentation and the anti-nephrin AB story. https://t.co/CKUv4DNpnl
RT @dr_ukio: ★FLOW試験の結果がERA /NEJMで同時発表されました！ 2型DM+CKD (eGFR 25-75 / UACR 100-5000) 3533人(66歳、アジア24%) セマグルチド注射1.0mg vs プラセボ 3.4年 主要複合イベント(…
2型糖尿病患者の慢性腎臓病に対する皮下セマグルチド vs プラセボ（3.4年追跡） ・腎疾患イベント：HR=0.71 [95%CI: 0.56-0.89] ・eGFRの低下：年間1.16mL/1.73/m2ほど緩やか N Engl J Med . 2024 May 24. Online ahead of print. PMID:38785209 https://t.co/POYajXr45Y
Trending on PubMed: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. https://t.co/uRVMaOFeaN
Best of #ERA2024 is yet to come We are honoured to host @KatherineTuttl8 @Tobias_B_Huber @valerie_luyckx Friday 7:15 PM MEST (later on demand) for a detailed post-congress discussion! Academic partners @NDTsocial @hjanders_hans @MarcusSaemann @AKronbichler https://t.co/bwNtmxcSqV
They also found: - a slower decline in kidney function - 18% lower risk of cardiovascular event - 20% reduced risk of death from any cause https://t.co/HccISZbp7X
う〜ん。これも研究デザインの闇よなぁ。複合アウトカムは、イベント発生数で重みづけするべきだと思うんだけど、どう思う？ Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes https://t.co/HuWSMgNnTQ
RT @Mattjones0203: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine http…
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. https://t.co/IgCwu3uW1j
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes | New England Journal of Medicine https://t.co/pIBeo6XU3J
@ssrna 感覺現在減肥藥被炒成神藥（好心動？ https://t.co/ntmf8kP7xL
RT @gunnar_heine: Freitag Vormittag #FLOW Samstag Nachmittag #SELECT Renal Sonn-Abend All at HOMe https://t.co/LNfipfiF7d FLOW: https://…
RT @gunnar_heine: Freitag Vormittag #FLOW Samstag Nachmittag #SELECT Renal Sonn-Abend All at HOMe https://t.co/LNfipfiF7d FLOW: https://…
RT @gunnar_heine: Freitag Vormittag #FLOW Samstag Nachmittag #SELECT Renal Sonn-Abend All at HOMe https://t.co/LNfipfiF7d FLOW: https://…
Freitag Vormittag #FLOW Samstag Nachmittag #SELECT Renal Sonn-Abend All at HOMe https://t.co/LNfipfiF7d FLOW: https://t.co/OPghOXF94q SELECT Renal: https://t.co/DvGqwctjCn Danke, Professor Johannes Mann! @dgfn_ev @oegnephro @com_SFNDT @MarcusSaemann @dguerrot @AKronbichler https://t.co/pk7lqsmbGP
all in - FLOW Es ist eine große Freude und Ehre für uns, wenige Stunden nach der Publikation auf #ERA2024 und im @NEJM mit Professor Mann die #FLOW Studie zu diskutieren. Akademische Partner: @dgfn @oegn @sfndt https://t.co/XKgBxhfYWT via @YouTube
RT @dr_ukio: ★FLOW試験の結果がERA /NEJMで同時発表されました！ 2型DM+CKD (eGFR 25-75 / UACR 100-5000) 3533人(66歳、アジア24%) セマグルチド注射1.0mg vs プラセボ 3.4年 主要複合イベント(…
RT @P_Rossing: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. https://t.co/nt6HOua6ET
RT @dr_ukio: ★FLOW試験の結果がERA /NEJMで同時発表されました！ 2型DM+CKD (eGFR 25-75 / UACR 100-5000) 3533人(66歳、アジア24%) セマグルチド注射1.0mg vs プラセボ 3.4年 主要複合イベント(…
★FLOW試験の結果がERA /NEJMで同時発表されました！ 2型DM+CKD (eGFR 25-75 / UACR 100-5000) 3533人(66歳、アジア24%) セマグルチド注射1.0mg vs プラセボ 3.4年 主要複合イベント(透析,移植,eGFR<15, eGFR 50%低下, 腎関連or心血管死亡)は HR 0.76 (0.66～0.88)と低下 https://t.co/mmlZ9JSvG1 https://t.co/XRmTVb45Hw https://t.co/VXRsdeAI3U
8. Journal The New England Journal of Medicine **utilizing generative AI: ChatGPT-4o** https://t.co/T5BZMgDqA3
Happy #FLOW trial publication day to all who celebrate ? Effects of Semaglutide on CKD in Pts w/ DMT2 @NEJM Reduction in: Primary composite kidney outcomes ? GFR slope ? CV Death ? All cause death ? @hswapnil.bsky.social #ERA24 #NephSky www.nejm.org/doi/full/10....
RT @P_Rossing: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. https://t.co/nt6HOua6ET
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. https://t.co/nt6HOua6ET
Biggest story of 2024 just blasted @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2403347 -- GLP1RA for CKD with diabetics.. Another win for Nephrology !!!!
This is a very light tea that helps support liver & kidney detox by Arbonne! ... support your immune system with essential vitamins Ask me how ...
... 10.1056/NEJMoa2403347 (kidney disease) 10.1056/NEJMoa2404881 (sleep apnea) ... I'm here as extra support through your journey, helping you meet your ...
The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. ... doi:10.1056/NEJMoa2403347; Ridker PM. From C- ...
... additional 8.9% vs glargine. 3. For practice, Ikizler stressed an ... 10.1056/NEJMoa2403347. 2. Zoungas S, D'Alessio D, Pavo I, et al. A ...
10.1056/NEJMoa2403347 (kidney disease) 10.1056/NEJMoa2404881 (sleep ... Information can tell you what to do, but it can't change ...
... supporting your hormonal and metabolic health too. They ... DOI: 10.1056/NEJMoa2403347 #DraFerCarballar #Riñon #LunesDeEndoTip #Semaglutida ...
... supplement သောက်တဲ့အတွက် guideline ဖြစ်ပါတယ်။ ... org/doi/10.1056/NEJMoa2403347) ဤရလဒ်များကြောင့် ...
https://doi.org/10.1056/nejmoa2403347 7. [Engineering] Improved ... ▪️ Providing balanced information on both the risks of medication and the ...
... 10.1056/NEJMoa2403347 · SURMOUNT-OSA 10.1056/NEJMoa2404881 · STEP 9 10.1056/NEJMoa2403664 · alcohol use disorder 10.1001/jamapsychiatry.
Citations: SELECT 10.1056/NEJMoa2307563 · SELECT weight independent analysis 10.1016/S0140-6736(25)01375-3 · FLOW 10.1056/NEJMoa2403347 · ...
But here's the truth: your kidneys are working for you every minute of every day—and the choices you make today can help support their health ...
مركز المعلومات الدوائية المركزي بالبحيرة Beheira drug information center ... additional glycemic/CV benefit. KDIGO 2022 guideline: initiate an ...
From supporting blood sugar regulation and metabolic health to ... DOI: 10.1056/NEJMoa2403347. #fyve #healthyaging #everydaywellness ...
Exploratory gut microbiome analyses were also conducted (see Supplemental Materials). ... https://doi.org/10.1056/nejmoa2403347 7. [Engineering]
Source: New England Journal of Medicine https://doi.org/10.1056/nejmoa2403347 7. [Engineering] Improved charge extraction in inverted perovskite ...
... [Materials Science] Two-dimensional Sc2N MXenes as efficient solid ... https://doi.org/10.1056/nejmoa2403347 7. [Engineering] Improved ...
... additional options for patients who: Need greater LDL reduction ... doi:10.1056/NEJMoa2403347. 3. Sanyal AJ, et al. Phase 3 trial of ...
Semaglutide and chronic kidney disease in type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109–121. doi:10.1056/NEJMoa2403347. 3. Sanyal AJ, et ...
Information & appointments: +39 348 228 2548 ... Perkovic et al., NEJM (2024) – Studio FLOW, protezione renale. DOI: 10.1056/NEJMoa2403347.
1. Recent posts. Medical World Dr Rana Sanjay. 19w · Public · #Semaglutide Linked to Better Quality of Life in Diabetes and Kidney ...
org/doi/full/10.1056/NEJMoa2403347 https://www.adameetingnews.org ... Want general information about wellness-based weight support programs?
DOI: 10.1056/NEJMoa2403347. 5. American Diabetes Association (2026) ... (2025) – Nutritional Priorities to Support GLP-1 Therapy for Obesity.
https://www.nejm.org/doi/abs/10.1056/NEJMoa2403347. This one also ... An extra 15 lbs then you're used to shouldn't really be a concern ...
Citations: SELECT 10.1056/NEJMoa2307563 · SELECT weight independent analysis 10.1016/S0140-6736(25)01375-3 · FLOW 10.1056/NEJMoa2403347 · ...
doi:10.1056/nejmoa2403347. 4. Shor R, Mihalache A, Noori A, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age ...
New England Journal of Medicine 391(2); 109-121. doi:10.1056/NEJMoa2403347. Pillarisetti, L., & Agrawal, D. K. (2025). Semaglutide: Double-edged ...
For more information, visit the JAMA website and customize your ... support kidney health by reducing inflammation and fibrosis. Trial ...
doi: 10.1056/NEJMoa2403347. pmid:38785209. 10. Marx N, Husain M ... Supporting Information · LaTeX · Other Article Types · Preprints · Revising ...
doi: 10.1056/NEJMoa2403347. Further Reading. All Semaglutide Content ... Please note that medical information found on this website is designed to ...
Supplementary Medicine · Health Overview · View All Health · Sports ... https://doi.org/10.1056/nejmoa2403347. Novo Nordisk is a registered ...
For more information ... Researchers estimated that semaglutide provided the equivalent of approximately eight additional days of full health per ...
org/doi/full/10.1056/NEJMoa2403347 Conclusion: Semaglutide reduced the risk of clinically important kidney outcomes and death from ...
org/doi/full/10.1056/NEJMoa2403347 Conclusion: Semaglutide reduced the risk of clinically important kidney outcomes and death from ...
It would be interesting to see how many drop outs were there with cholecytitis or pancreatitis from semaglutide as it is a well known ...
https://doi.org/10.1056/nejmoa2403347; Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022. 12(1): 7 ...
2024 #ERA24 #Nephpearls https://www.nejm. org/doi/full/10.1056/NEJMoa2403347 · No photo description available. 20 · Like. Recent posts ...
... support a therapeutic role for semaglutide in this population," the researchers concluded. ... 10.1056/NEJMoa2403347. Comment. Please enable ...
EL
N
DA
B
SD
AM
FB
LJ
TL
JD
秀
MN
I
LL
SH
AT
AI
LR
KM
B
AA
J
S
SN
GD
MC
VB
R
SA
W
F
SM
Aب
YS
MS
JT
JW
AM
NG
CF
A
JR
MZ
CH
RG
KR
DS
SF
JB
K
LO
GC
木
JF
YF
AF
EL
MM
GH
GS
G
G
GM
CH
ク
SI
JM
น
O
BT
DD
CM
KP
真心
ぽ
BJ
KF
LR
CD
ZB
IM
MM
AP
AL
GW
VL
VV
AM
R
G
SS
DF
KD
HE
İB
ID
LG
ET
MA
DA
AK
HD
JM